Cellectis (CLLS) Interest Expenses (2021 - 2026)
Cellectis (CLLS) posted quarterly Interest Expenses of -$4.4 million for Q1 2026, up 56.63% year-over-year from -$2.8 million in Q1 2025, and down 104.9% quarter-over-quarter from $90.7 million in Q4 2025.
Analysis
Cellectis (CLLS) Interest Expenses (2021 - 2026) Analysis & Trends
Cellectis' Interest Expenses history runs 12 years deep, the most recent figure standing at -$4.4 million for Q1 2026.
- In Q1 2026, Interest Expenses rose 56.63% year-over-year to -$4.4 million; the TTM figure through Mar 2026 stood at $55.7 million (up 1555.4% YoY), while the FY2025 annual figure was $51.1 million, up 136.25% from the prior year.
- Interest Expenses for Q1 2026 stood at -$4.4 million, down from $90.7 million in the prior quarter.
- The five-year high for Interest Expenses was $90.7 million in Q4 2025, with the low at -$19.7 million in Q2 2025.
- The 5-year median for Interest Expenses is -$3.1 million (2024), against an average of $8.2 million.
- The sharpest annual moves came in 2022 and 2023: Interest Expenses plunged 1134.55% in 2022, then jumped 2221.78% in 2023.
- Cellectis' Interest Expenses stood at $22.0 million in 2022, then jumped by 190.28% to $63.7 million in 2023, then decreased by 28.35% to $45.7 million in 2024, then jumped by 98.68% to $90.7 million in 2025, then sank by 104.9% to -$4.4 million in 2026.
- Business Quant data shows CLLS's Interest Expenses at -$4.4 million in Q1 2026, $90.7 million in Q4 2025, and -$10.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Cellectis | 321.90 Mn | 155.05 Mn | - | -3.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.01 Mn |
| Mar 31, 2026 | -4.44 Mn |
| Dec 31, 2025 | -11.41 Mn |
| Sep 30, 2025 | -10.91 Mn |
| Jun 30, 2025 | -19.70 Mn |
| Mar 31, 2025 | -10.25 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Sep 30, 2024 | -15.41 Mn |
| Jun 30, 2024 | 16.65 Mn |
| Mar 31, 2024 | -3.14 Mn |
| Dec 31, 2023 | -17.56 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | 16.28 Mn |
| Mar 31, 2023 | -5.18 Mn |
| Dec 31, 2022 | -13.68 Mn |
| Sep 30, 2022 | -1.09 Mn |
| Jun 30, 2022 | 1.69 Mn |
| Mar 31, 2022 | -1.36 Mn |
| Mar 31, 2021 | -1,000.00 |